Selective BLT2 Agonists for Inflammatory Skin Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory skin diseases, such as psoriasis, often rely on anti-inflammatory and immune-suppressive drugs, which can lead to adverse side effects and slow wound healing.
Innovation Solution
Development of novel compounds acting as selective agonists of the leukotriene B4 receptor 2 (BLT2), which are designed to improve wound healing and reduce pain in inflammatory skin diseases, with a focus on enhancing solubility, metabolic stability, and pharmacokinetic profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory and immune-suppressive drugs are used to treat chronic inflammatory skin diseases, then inflammation is reduced, but wound healing is slowed and adverse side effects occur
Solution Approach 1:
The patent extracts and isolates the specific BLT2 receptor pathway from the general inflammatory response system. By designing selective BLT2 agonists that target only this specific receptor subtype, the treatment can reduce inflammation through the LTB4-BLT2 pathway without affecting other inflammatory mediators and wound healing processes, thereby resolving the contradiction between inflammation reduction and wound healing promotion
Solution Approach 2:
The patent applies local quality by creating compounds with selective affinity for BLT2 receptor rather than broad-spectrum anti-inflammatory activity. The synthesized compounds exhibit selective binding to BLT2 with minimal cross-reactivity to other receptors, allowing localized anti-inflammatory action in specific tissue contexts while preserving overall wound healing capacity
2Object-affected harmful factors
If broad-spectrum anti-inflammatory drugs are used, then inflammation is controlled, but adverse side effects increase
Solution Approach 1:
The patent extracts the specific BLT2 receptor target from the complex inflammatory system and designs agonists that selectively modulate only this pathway. This selective targeting eliminates the need for broad immune suppression, thereby controlling inflammation through a dedicated pathway while avoiding the adverse side effects associated with non-selective anti-inflammatory drugs
Solution Approach 2:
The patent introduces selective BLT2 agonists as intermediary compounds that specifically mediate the LTB4-BLT2 signaling pathway. These compounds act as precise intermediaries to transmit anti-inflammatory signals through the BLT2 receptor without triggering off-target effects, thereby controlling inflammation while minimizing adverse side effects
3Reliability
If existing BLT2 agonists are used, then some therapeutic effect is achieved, but pharmacokinetic profile and solubility are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of BLT2 agonists, including variations in core scaffolds, substituent groups, and molecular weight. These structural parameter changes were optimized to simultaneously improve solubility, metabolic stability, and pharmacokinetic properties while preserving or enhancing therapeutic efficacy at the BLT2 receptor
Solution Approach 2:
The patent employs composite molecular structures combining different heterocyclic rings, aromatic systems, and functional groups to create novel BLT2 agonists. These composite molecular architectures provide enhanced solubility characteristics and metabolic stability compared to simpler structures, while maintaining high affinity and selectivity for the BLT2 receptor
Data Source
Figure 1A~2
Figure 3~4
Figure 5~6
AI summary
Herein, compounds of Formulae (I-a) and (II) that act as selective agonists of the leukotriene B4 receptor 2 (BLT2) receptor are presented. The invention pertains to these compounds, their synthesis, as well as their medical use, amongst others in the treatment of pain and inflammatory skin diseases such as psoriasis.